IVF success rates are among the most misunderstood numbers in reproductive medicine. Clinics publish them prominently, patients compare them obsessively, and yet the same percentage figure can mean four entirely different things depending on how it was calculated. This guide explains what the data actually shows, why age dominates the outcome curve, and how to evaluate any clinic's published results with the same rigor a reproductive endocrinologist would apply.
What IVF Success Rates Actually Measure
The first question to ask when a clinic quotes you a success rate is: success at what, exactly? For a guide to interpreting and comparing these numbers, see how to read IVF success rates.
Four distinct metrics are reported in IVF literature, and they are not interchangeable.
Live birth rate is the only number that answers the question most patients are actually asking — what are the odds I go home with a baby? It counts cycles that result in the birth of at least one living infant, divided by the number of cycles started (or sometimes by the number of transfers performed). Because it captures every loss between retrieval and birth — failed fertilization, arrested embryos, failed implantation, miscarriage, stillbirth — it is the most conservative and the most clinically honest metric. It is the one published by the CDC and SART, and it is the only number worth comparing across clinics.
Clinical pregnancy rate counts cycles in which a fetal heartbeat was confirmed by ultrasound at six to seven weeks. This is a legitimate intermediate endpoint for research purposes but inflates apparent success because it excludes subsequent pregnancy losses. A clinic with a 55% clinical pregnancy rate and a 38% live birth rate has a miscarriage rate that should prompt questions.
Implantation rate measures the percentage of transferred embryos that produce a gestational sac. It is useful for comparing laboratory performance across embryo cohorts but tells you nothing about whether that pregnancy will continue.
Biochemical pregnancy rate counts any cycle producing a detectable rise in serum hCG, including chemical pregnancies that resolve before a sac is ever visible. This metric is almost never clinically actionable for patients comparing clinics.
When a clinic advertises a headline rate without specifying which metric it represents, ask directly. A reputable practice will point you to its SART or CDC profile without hesitation.
IVF Live Birth Rates by Age — CDC 2022 Data
The CDC 2022 ART Surveillance Report is the definitive national dataset for IVF outcomes in the United States. It captures all cycles performed at reporting clinics and stratifies results by patient age, cycle type, and diagnosis. The 2022 data, published in 2024, represents the most current complete picture available.
| Age Group | Live Birth Rate | Cycles Reported |
|---|---|---|
| Under 35 | 51.4% | ~85,000 |
| 35–37 | 37.2% | ~38,000 |
| 38–40 | 22.6% | ~32,000 |
| 41–42 | 12.1% | ~18,000 |
| Over 42 | 4.6% | ~12,000 |
Source: CDC 2022 ART Surveillance Report. Rates reflect fresh, non-donor embryo transfers using the patient's own eggs.
These are national averages across all U.S. reporting clinics. High-volume academic medical centers and specialized reproductive endocrinology practices with optimized laboratory protocols routinely outperform the national average by 10 to 15 percentage points within each age bracket. Conversely, clinics accepting a higher proportion of patients with diminished ovarian reserve, prior failed cycles, or complex diagnoses will report rates below the national mean — a reflection of their patient population, not necessarily their clinical quality.
Why Age Is the Dominant Variable
No other single factor predicts IVF outcomes as reliably as patient age. The mechanism is primarily chromosomal, not uterine.
Chromosomal Aneuploidy
As oocytes age within the ovary, the spindle apparatus responsible for accurate chromosome separation during meiosis becomes less reliable. The result is a higher rate of aneuploid eggs — eggs carrying the wrong number of chromosomes. Embryos derived from aneuploid eggs either fail to implant, arrest in early development, or miscarry.
A landmark analysis by Franasiak et al. published in Fertility and Sterility (2014), examining over 15,000 blastocysts biopsied for preimplantation genetic testing, found that aneuploidy rates correlate tightly with maternal age: approximately 35% of blastocysts at age 35, rising to more than 70% by age 42. This is why live birth rates fall so steeply with age even when stimulation produces a similar number of follicles — the percentage of usable embryos within that cohort is shrinking.
Ovarian Reserve Decline
Alongside egg quality, the sheer number of retrievable eggs decreases with age. Anti-Müllerian hormone (AMH), secreted by small antral follicles, is the most widely used marker of ovarian reserve. AMH declines continuously from the mid-twenties onward and falls sharply after 37. A lower AMH means fewer follicles recruited per stimulation cycle, fewer eggs retrieved, and therefore fewer embryos available for selection and transfer.
The ASRM guidelines on age and fertility note that this decline is population-level and that individual variation is significant — some 38-year-olds have AMH levels typical of a 32-year-old, and vice versa. Ovarian reserve testing (AMH plus antral follicle count by transvaginal ultrasound) provides a personalized baseline that is more clinically useful than age alone.
What Age Does Not Affect
Uterine receptivity is relatively well-preserved with advancing age. The endometrium's capacity to support implantation and sustain a pregnancy remains largely intact into the mid-fifties in women with properly prepared endometria. This is the physiological basis for donor egg IVF, discussed below.
Fresh vs. Frozen Embryo Transfers
IVF cycles can result in a fresh embryo transfer — performed in the same cycle in which eggs are retrieved — or a frozen embryo transfer (FET), in which embryos are cryopreserved and transferred in a subsequent cycle after the body has recovered from stimulation.
The balance of evidence now favors frozen transfers in most clinical scenarios. The primary reason is endometrial receptivity. Ovarian stimulation with gonadotropins alters the hormonal environment during the retrieval cycle, often producing a progesterone rise that advances endometrial development ahead of the embryo's developmental stage. In a frozen cycle, the endometrium is prepared under controlled hormonal conditions — typically estradiol followed by progesterone — without the confounding effects of stimulation.
| Transfer Type | Live Birth Rate (approx.) | Key Considerations |
|---|---|---|
| Fresh transfer | 45–51% (under 35) | Faster to first transfer; no freeze/thaw step; endometrium may be suboptimal |
| Frozen embryo transfer (FET) | Comparable to or higher than fresh in most age groups | Additional 4–6 week wait; allows PGT-A testing; better endometrial synchrony |
The CDC's primary reporting has historically emphasized fresh transfer outcomes, but frozen transfer cycles are increasingly reported separately as FET volumes have grown to exceed fresh transfers nationally. When reviewing a clinic's SART or CDC profile, review both fresh and frozen transfer data and clarify which cycle type the clinic recommends for your situation.
PGT-A: Does Genetic Testing Improve Success Rates?
Preimplantation genetic testing for aneuploidies (PGT-A) involves biopsying five to eight cells from the trophectoderm — the outer layer of a blastocyst that will become the placenta — and analyzing the chromosomal content before transfer. Embryos confirmed to have the correct number of chromosomes (euploid embryos) are then prioritized for transfer.
The Evidence for PGT-A
The primary benefit of PGT-A is well-established: transferring a euploid embryo significantly increases the live birth rate per transfer and reduces the miscarriage rate from the untested baseline of 25–40% down to approximately 9–12%. For women over 37, for whom aneuploidy rates are high enough that the majority of untested embryos may be abnormal, PGT-A provides a meaningful clinical advantage by avoiding transfers that are unlikely to succeed.
The ASRM position on preimplantation genetic testing identifies the strongest indications as: women over 37, patients with recurrent implantation failure (two or more failed transfers of morphologically good-quality embryos), and patients with recurrent pregnancy loss.
The Important Caveat
PGT-A improves per-transfer success rates but does not necessarily improve cumulative success rates — the probability of achieving a live birth after completing a full stimulation cycle and using all resulting embryos. Because testing requires biopsying and freezing all embryos, it adds cost ($3,000–$6,000 per cycle), a freeze-thaw step, and the possibility that no embryos survive to the biopsy stage or that all are reported aneuploid. For younger patients with good prognosis, some data suggest that carefully selected, untested blastocysts perform comparably to tested ones over multiple transfers.
The decision to pursue PGT-A should be individualized based on age, embryo numbers, prior history, and the specific clinical recommendation of your reproductive endocrinologist.
Donor Egg IVF — When It Changes Everything
When the limiting factor in IVF is egg quality — as it increasingly becomes after age 40 — donor egg IVF fundamentally shifts the outcome equation. In donor egg cycles, the eggs come from a younger woman (typically under 30, screened extensively for genetic and infectious diseases), and the resulting embryos are transferred to the recipient's uterus.
Because success is driven by the donor's egg quality rather than the recipient's age, live birth rates in donor egg cycles are largely independent of how old the recipient is. Published data from the SART registry consistently show live birth rates of approximately 45–55% per transfer for donor egg cycles when the egg donor is under 30, regardless of whether the recipient is 38 or 48.
This is not a statistical artifact. It reflects the underlying biology: the uterus in its 40s is fully capable of supporting a pregnancy when given a chromosomally normal embryo to implant. For patients who have not achieved success with their own eggs after appropriate trials, or whose ovarian reserve testing suggests a very poor prognosis, donor egg IVF is not a last resort — it is often the most direct path to a live birth.
If you are considering this path, egg freezing by young donors uses the same vitrification technology used to preserve embryos, and outcomes with vitrified donor eggs are now equivalent to fresh donor egg cycles at experienced programs.
Cumulative Success Rates — Multiple Cycles
Single-cycle live birth rates, while the standard unit of comparison, substantially understate the probability of success for patients who complete a full course of treatment. Most patients who do not succeed in their first cycle have a meaningful probability of success in subsequent cycles, particularly when the clinical team adjusts stimulation protocols based on prior response.
A seminal analysis by Malizia et al. published in JAMA (2009) followed 6,164 patients through up to six IVF cycles and found that cumulative live birth rates after three cycles reached approximately 65% for women under 40. The incremental benefit of each additional cycle was not uniform — patients with prior success had higher subsequent success rates — but even patients who had failed two cycles had a meaningful probability of success in a third.
The practical implication is this: if you are quoted a 35% success rate for your age group and cycle type, that does not mean a 65% chance of permanent failure. Depending on how many cycles you are prepared to undertake and how your prognosis evolves with each attempt, the cumulative probability of achieving a live birth may be substantially higher.
How to Read a Clinic's Published Success Rates
Both SART (sartcorsonline.com) and the CDC (cdc.gov/art/artdata/index.html) publish clinic-level outcome data annually. These databases are the most objective source of comparative information available to patients. Here is how to use them effectively.
Filter to Your Specific Age Group
A clinic's headline success rate is an average across all patients and all ages. Because age is the strongest predictor of outcome, a clinic treating a disproportionately young patient population will show inflated rates relative to a clinic treating a typical mix. Always filter to the 5-year age bracket that matches your own age at cycle start.
Look at Cycles Started, Not Just Transfers
Live birth rate per transfer and live birth rate per retrieval are different numbers, and the gap between them reveals important information. A clinic that aggressively cancels cycles before retrieval (due to poor stimulation response) or that does not transfer embryos when development is suboptimal will show a higher rate per transfer but a lower rate per cycle started. The rate per retrieval started is the more clinically honest denominator.
Check the Cancellation Rate
The cancellation rate — the proportion of cycles that do not reach egg retrieval — is a surrogate for how rigorously a clinic screens and how willing they are to proceed with suboptimal stimulation responses. A cancellation rate above 12% warrants a direct question about the clinic's patient selection criteria and stimulation protocols.
Account for Patient Mix
Clinics that accept patients with diminished ovarian reserve, multiple prior failed cycles, or complex diagnoses will inevitably report lower raw success rates. When choosing a fertility clinic, ask specifically how a clinic adjusts for patient complexity in their reported outcomes, and ask for success rates within your specific age bracket and primary diagnosis — not just the overall rate.
Verify Laboratory Accreditation
The embryology laboratory is the most consequential variable in IVF success that is not captured in age statistics. Ask whether the laboratory holds College of American Pathologists (CAP) accreditation and CLIA certification. Ask about the lab director's training and years of experience. A clinic with good success rates but a high staff turnover in the embryology lab is a different risk proposition than one with a stable, experienced team.
What Factors Within Your Control Affect Outcomes
While age is the dominant variable, several modifiable factors have meaningful evidence behind them.
Body mass index. Both underweight and obese BMI are associated with lower IVF success rates, longer time to stimulation response, and higher rates of cycle cancellation. The ASRM practice guidelines recommend optimizing BMI before initiating IVF, particularly for patients at the extremes of the normal range.
Smoking. Active smoking is one of the most clearly documented modifiable risk factors for reduced IVF success. Studies consistently show that smokers have approximately 30% lower live birth rates per cycle compared to non-smokers, independent of age. This effect appears to be mediated by direct toxicity to oocytes and embryos. Cessation at least three months before retrieval is strongly advised.
Laboratory quality. While this is partially outside patient control once a clinic is chosen, it is within your control to select a clinic with demonstrably strong laboratory metrics. Ask about fertilization rates, blastocyst development rates, and the frequency of total fertilization failure. These process metrics often reveal laboratory quality that outcome data alone may not capture.
Protocol optimization. Stimulation protocols are not one-size-fits-all. Poor responders may benefit from different gonadotropin formulations, adjuvant approaches such as growth hormone, or modified protocols (antagonist vs. agonist). After any cycle that does not produce the expected number of eggs or embryos, a detailed protocol review is warranted before proceeding.
Male factor infertility is present in up to 50% of infertile couples and can affect fertilization rates, embryo quality, and ultimately live birth rates even when IVF is used. A complete semen analysis and, where indicated, a sperm DNA fragmentation test should be completed early in the evaluation process — not as an afterthought after female workup is complete.
Frequently Asked Questions
How many IVF cycles does it typically take to have a baby?
There is no universal answer, but the cumulative data are instructive. Research published in JAMA shows that after three complete IVF cycles, approximately 65% of women under 40 achieve a live birth. For older patients, the cumulative probability is lower per cycle but still meaningful across multiple attempts, particularly if a transition to donor eggs is considered. Most reproductive endocrinologists recommend evaluating and adjusting your protocol after each cycle rather than repeating an identical approach.
Is a day-3 or day-5 embryo transfer better?
Blastocyst-stage (day-5 or day-6) transfers are associated with higher live birth rates per transfer in patients with sufficient embryo numbers. Extending embryos to the blastocyst stage allows for additional natural selection — embryos with development arrest are identified in the lab rather than after transfer. However, for patients with very few embryos, extending to day 5 carries the risk of losing embryos that might have survived to implantation in the uterine environment. Your clinic should individualize this decision based on embryo numbers, morphology, and prior cycle history.
What live birth rate should I expect from a good clinic?
For women under 35 using their own eggs, look for clinics reporting live birth rates at or above the national average of 51% per retrieval in the CDC or SART databases. Rates well below the national average warrant a deeper look at patient mix and laboratory quality. Rates that appear dramatically higher than the national average — particularly above 65% — may reflect favorable patient selection rather than superior clinical outcomes, and deserve the same scrutiny.
Should I do PGT-A genetic testing on my embryos?
PGT-A is most strongly supported for women over 37, patients with recurrent implantation failure, and those with a history of recurrent pregnancy loss. For younger patients with good prognosis and a reasonable embryo cohort, the evidence that PGT-A improves cumulative live birth rates is less clear, and the additional cost and logistical complexity may not be justified. The ASRM position on PGT-A provides a detailed framework for this decision that is worth reviewing with your reproductive endocrinologist.
